

Product datasheet for **TP501089**

Ube2w (NM_025773) Mouse Recombinant Protein

Product data:

Product Type:	Recombinant Proteins
Description:	Purified recombinant protein of Mouse ubiquitin-conjugating enzyme E2W (putative) (Ube2w), with C-terminal MYC/DDK tag, expressed in HEK293T cells, 20ug
Species:	Mouse
Expression Host:	HEK293T
Expression cDNA Clone or AA Sequence:	>MR201089 protein sequence Red =Cloning site Green =Tags(s)
	MASMQKRLQKELLALQNDPPPGMTLNEKSVQNSITQWIVDMEGAPGTLYEGEKFQLLFKSSRYPFDSPQ VMFTGENIPIHPHVYSNGHICLSILTEDWSPALSVQSVCLSIISMLSSCKEKRRPPDNSFYVRTCNKNPK KTKWWYHDDTC
	TRTRPLEQKLISEEDLAANDILDYKDDDDKV
Tag:	C-MYC/DDK
Predicted MW:	17.3 kDa
Concentration:	>0.05 µg/µL as determined by microplate BCA method
Purity:	> 80% as determined by SDS-PAGE and Coomassie blue staining
Buffer:	25 mM Tris-HCl, 100 mM glycine, pH 7.3, 10% glycerol
Note:	For testing in cell culture applications, please filter before use. Note that you may experience some loss of protein during the filtration process.
Storage:	Store at -80°C after receiving vials.
Stability:	Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
RefSeq:	<u>NP_080049</u>
Locus ID:	66799
UniProt ID:	<u>Q8VDW4</u> , <u>A0A0A0MQF3</u>
RefSeq Size:	3139
Cytogenetics:	1 A3



[View online »](#)

RefSeq ORF: 456

Synonyms: 6130401J04Rik

Summary: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. Specifically monoubiquitinates the N-terminus of various substrates, including ATXN3, MAPT/TAU, POLR2H/RPB8 and STUB1/CHIP, by recognizing backbone atoms of disordered N-termini (PubMed:21855799, PubMed:21229326). Involved in degradation of misfolded chaperone substrates by mediating monoubiquitination of STUB1/CHIP, leading to recruitment of ATXN3 to monoubiquitinated STUB1/CHIP, and restriction of the length of ubiquitin chain attached to STUB1/CHIP substrates by ATXN3 (PubMed:21855799). After UV irradiation, but not after mitomycin-C (MMC) treatment, acts as a specific E2 ubiquitin-conjugating enzyme for the Fanconi anemia complex by associating with E3 ubiquitin-protein ligase FANCL and catalyzing monoubiquitination of FANCD2, a key step in the DNA damage pathway (PubMed:21229326). In vitro catalyzes 'Lys-11'-linked polyubiquitination. UBE2W-catalyzed ubiquitination occurs also in the presence of inactive RING/U-box type E3s, i.e. lacking the active site cysteine residues to form thioester bonds with ubiquitin, or even in the absence of E3, albeit at a slower rate (By similarity).[UniProtKB/Swiss-Prot Function]